난치성, 재발성 Clostridium difficile 감염에서 대변세균총이식: 9예의 임상증례보고

• Published in: The Korean journal of gastroenterology Vol. 69; no. 4; pp. 226 - 231
• Main Authors: 방병욱, Byoung Wook Bang, 박진석, Jin-seok Park, 김형길, Hyung Kil Kim, 신용운, Yong Woon Shin, 권계숙, Kye Sook Kwon, 권해윤, Hea Yoon Kwon, 백지현, Ji Hyeon Baek, 이진수, Jin-soo Lee
• Format: Journal Article
• Language: Korean
• Published: 대한소화기학회 30.04.2017
• Subjects: Clostridium difficile; Colonoscopy; Fecal microbiota transplantation; Gastrointestinal microbiome
• ISSN: 1598-9992

Background/Aims: Fecal microbiota transplantation (FMT) is a highly effective therapy for refractory and recurrent Clostridium difficile infection (CDI). Despite its excellent efficacy and recent widespread use, FMT has not been widely used in South Korea thus far. We describe our experience with FMT to treat refractory/recurrent CDI. Methods: We conducted a chart review of patients who underwent FMT for refractory/recurrent CDI at Inha University Hospital, between March 2014 and June 2016. The demographic information, treatment data, and adverse events were reviewed. FMT was administered via colonoscopy and/or duodenoscopy. All stool donors were rigorously screened to prevent infectious disease transmission. Results: FMT was performed in nine patients with refractory/recurrent CDI. All patients were dramatically cured. Bowel movement was normalized within one week after FMT. There were no procedure-related adverse events, except aspiration pneumonia in one patient. During the follow-up period (mean 11.4 months), recurrence of CDI was observed in one patient at one month after FMT due to antibiotics. Conclusions: FMT is a safe, well-tolerated and highly effective treatment for refractory/recurrent CDI. Although there are many barriers to using FMT, we expect that FMT will be widely used to treat refractory/recurrent CDI in South Korea. (Korean J Gastroenterol 2017;69:226-231)